Rapamycin Alkyl Ether Isomers for Reduced Nephrotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current rapamycin analogs exhibit unsatisfactory side effects such as nephrotoxicity, and there is a need for novel isomers and 42-epimers with different polarity and stability properties to enhance their efficacy and safety, particularly for local delivery and drug device combinations.
Innovation Solution
Development of semisynthetic isomers and 42-epimers of rapamycin alkyl ether analogs through fermentation or synthetic methods, with specific structural modifications at the 15- and 42-positions, allowing for unique polarity and optical properties, and their use in pharmaceutical compositions for various treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional rapamycin analogs are used, then immunosuppressive activity is achieved, but nephrotoxicity and unsatisfactory side effects occur
Solution Approach 1:
The patent applies local quality by creating specific structural modifications at particular positions (C-15 and C-42) of the rapamycin molecule. The C-15 isomers and C-42 epimers introduce different functional groups at these specific locations to alter local chemical properties, thereby changing the overall pharmacological profile to reduce nephrotoxicity while maintaining immunosuppressive activity.
Solution Approach 2:
The patent employs parameter changes by systematically varying the stereochemical configuration at C-15 and C-42 positions, as well as modifying the alkyl ether substituents. These parameter changes in molecular structure lead to different polarity, solubility, and metabolic properties, enabling optimization of the drug's safety profile while preserving therapeutic efficacy.
2Object-affected harmful factors
If rapamycin analogs are modified to improve safety, then side effects are reduced, but stability and solubility properties change
Solution Approach 1:
The patent uses parameter changes to optimize both safety and stability by carefully selecting and varying the alkyl ether substituents at C-42 and the stereochemical configuration at C-15. Different alkyl chain lengths and configurations are tested to find the optimal balance between reduced side effects and maintained compound stability.
Solution Approach 2:
The patent creates composite molecular structures by combining the rapamycin core with various alkyl ether moieties at C-42 and specific stereochemical configurations at C-15. These composite structures allow for tailored properties where the alkyl ether groups provide solubility and stability characteristics while the modified core maintains immunosuppressive activity and reduces toxicity.
3Adaptability or versatility
If new isomers and epimers are synthesized, then unique polarity and optical properties are achieved, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the synthesis process into distinct steps: first establishing the C-15 isomer configuration, then introducing the C-42 epimerization, and finally adding the alkyl ether substituents. This segmented approach allows for controlled creation of specific stereochemical features and functional groups, making the complex molecule buildable from simpler precursors through modular transformations.
Solution Approach 2:
The patent employs preliminary action by first synthesizing the base rapamycin structure with the C-15 isomer configuration established, then performing epimerization at C-42 as a separate step, and finally introducing the alkyl ether groups. This sequence of preliminary actions allows each modification to be optimized independently, reducing the overall complexity of achieving the final complex structure with specific polarity and optical properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new isomers and 42-epimers demonstrate improved stability and solubility, potentially leading to different metabolic rates and efficacy in formulations, effectively addressing side effects and enhancing therapeutic outcomes for conditions like restenosis, immune disorders, and cancer.
Implementation Method 1
The compound cyclosporine (cyclosporin A) has found wide use since its introduction in the fields of organ transplantation and immunomodulation... Recently, several classes of macrocyclic compounds having potent immunomodulatory activity have been discovered. Okuhara et al., in European Patent Application No. 184,162, published Jun. 11, 1986, discloses a number of macrocyclic compounds isolated from the genus Streptomyces
Implementation Method 2
Development of semisynthetic isomers and 42-epimers of rapamycin alkyl ether analogs through fermentation or synthetic methods, with specific structural modifications at the 15- and 42-positions
Data Source
AI summary
Isomers and 42-epimers of rapamycin alkyl ether analogs and pharmaceutically acceptable salts or prodrugs thereof, are immunomodulatory agents and are useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosis, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. One particular preferred application of such isomers and 42-epimers of rapamycin alkyl ether analogs is in medicated devices and local vascular delivery wherein the stability and lipid solubility and subsequently diffusion through tissue and cell membranes are essential to the success of rapamycin containing combination devices.